Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XB010 in Advanced Solid Tumors
NCT06545331Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Aug 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of XB010 in solid tumor, Esophageal Squamous Cell Carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) and 3 more (3 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum Tolerated Dose and/or Recommended Dose for Expansion at 18 months, Safety of XB010 at 18 months and 3 more. Started Aug 2024; status: recruiting.
02
Drugs
XB010
03
Conditions
solid tumorEsophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT06545331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545331.